Tropical Weather Alert: For the latest updates on closures or modified hours for our UF Health clinical facilities, click here
About me
My name is Ashley Ghiaseddin, MD, and I’m a neuro-oncologist and chief of the division of neuro-oncology in UF’s Department of Neurosurgery. I specialize in brain cancer treatment, using targeted methods including chemotherapy, immunotherapy and precision medicine for patients with malignant brain tumors, such as glioblastoma.
I graduated with a bachelor’s degree in science and business from the University of Notre Dame and completed my medical degree at the University of Toledo. I went on to complete my residency at Indiana University and a neuro-oncology fellowship at Duke University.
I am a member of the Preston A. Wells Jr. Center for Brain Tumor Therapy, where I collaborate with an interdisciplinary team of experts dedicated to delivering patient-centered care and discovering better treatments for brain tumors.
In addition to taking care of patients, I conduct research into novel immunotherapy approaches to treat brain cancer and improve outcomes for patients. I am also interested in population-based studies involving glioblastoma and identifying ways to improve quality of life for patients and caregivers.
I am a leader in the neuro-oncology section of the American Academy of Neurology, and I am a member of the Society for Neuro-Oncology and the American Society of Clinical Oncology.
As a neuro-oncologist, I remain active in clinical trials as well as in authoring manuscripts. I run large investigator-initiated trials, and am currently serving as PI for multiple studies.
Conditions that I focus on treating include glioblastoma, astrocytoma, oligodendroglioma, cns lymphoma, ependymoma, neurocytoma and meningioma.
In my free time, I enjoy spending time with my family, walking, traveling and exploring Florida.
My locations
Active clinical trials
This study will enroll 6 DLT evaluable subjects (up to 12 patients total) where we will evaluate feasibility and safety of adoptive cellular therapy combined with IDH1/2 inhibitors in patients with recurrent or progressive oligodendroglioma WHO…
- Investigator
- Ashley Ghiaseddin
- Status
- Accepting Candidates
- Ages
- 18 Years - 89 Years
- Sexes
- All
This is a phase I study to assess the safety and feasibility of IL-8 receptor modified patient-derived activated CD70 CAR T cell therapy in CD70+ adult glioblastoma.
- Investigator
- Ashley Ghiaseddin
- Status
- Accepting Candidates
- Ages
- 18 Years - 80 Years
- Sexes
- All
The primary objective will be to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in (Stratum 1) adult patients with newly diagnosed GBM (MGMT low level or unmethylated in…
- Investigators
- Marcia B Hodik, Ashley Ghiaseddin
- Status
- Accepting Candidates
- Ages
- 4 Years - N/A
- Sexes
- All
My research
Top areas of exploration
- Brain Neoplasms , 11 publications
- Glioblastoma , 5 publications
- Glioma , 3 publications
- Anticonvulsants , 2 publications
Research activity
Accepted insurances
Please note: Some physicians and practices might not accept a specific insurance plan. Our list is also subject to change, and sometimes that change is not yet reflected in this list. Please contact the practice to confirm that your insurance is accepted. A representative will be happy to assist you.
See all insurancesMy areas of focus
Stories and news
Brain Cancer Awareness Month: Marissa vs. the Worst of the Worst
Marissa Valencia suddenly felt sick. Then, when she tried to speak, nothing that came out made sense. Her friend sitting across the table from her over lunch…
Grand Adventure: Tumor treatment ensures hike happens
In 2018, David Walther wanted to complete a rim-to-rim hike at the Grand Canyon in one day. He'd conquered the 21-mile hike four times before, but this time…